Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Change in Receivables (2021 - 2025)

Rxo (RXO) has disclosed Change in Receivables for 5 consecutive years, with $125.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 23.76% year-over-year to $125.0 million, compared with a TTM value of $5.0 million through Dec 2025, down 95.41%, and an annual FY2025 reading of $5.0 million, down 95.41% over the prior year.
  • Change in Receivables was $125.0 million for Q4 2025 at Rxo, up from $39.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $210.0 million in Q1 2022 and bottomed at -$122.0 million in Q2 2023.
  • Average Change in Receivables over 5 years is $294117.6, with a median of -$27.0 million recorded in 2024.
  • The sharpest move saw Change in Receivables surged 329.55% in 2024, then tumbled 692.86% in 2025.
  • Year by year, Change in Receivables stood at $141.0 million in 2021, then tumbled by 172.34% to -$102.0 million in 2022, then soared by 56.86% to -$44.0 million in 2023, then soared by 329.55% to $101.0 million in 2024, then rose by 23.76% to $125.0 million in 2025.
  • Business Quant data shows Change in Receivables for RXO at $125.0 million in Q4 2025, $39.0 million in Q3 2025, and -$83.0 million in Q2 2025.